Related Experiment Video
Updated: Jun 17, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Orlistat: current status in clinical therapeutics
Katie S McClendon1, Daniel M Riche, Gabriel Ikponmosa Uwaifo
1University of Mississippi, Department of Pharmacy Practice, Jackson, 39216, USA.
Expert Opinion on Drug Safety
|December 10, 2009
Summary
Orlistat is a safe and effective first-line pharmacotherapy for obesity management in adults and children. It offers beneficial effects on obesity-related co-morbidities with a mild adverse effect profile.
Area of Science:
- Pharmacology
- Obesity Medicine
- Clinical Therapeutics
Background:
- Obesity is a global epidemic with significant health and economic consequences.
- Obesity is associated with numerous co-morbidities that increase morbidity and mortality.
- Orlistat is an approved medication for obesity treatment and management of related conditions.
Purpose of the Study:
- To detail the pharmacotherapeutic role of orlistat in obesity.
- To describe orlistat's pharmacological properties and evidence base.
- To define orlistat's role in clinical practice for obesity management.
Main Methods:
- Comprehensive literature search for clinical trials, case reports, and meta-analyses.
- Evaluation of orlistat's safety and efficacy across diverse patient populations.
- Analysis of evidence for orlistat in obesity and associated co-morbidities.
Main Results:
- Orlistat exhibits a unique mechanism of action beneficial for obesity.
- Demonstrated positive effects on multiple obesity-related co-morbidity surrogates.
- Favorable safety profile with mild adverse effects and few drug interactions.
Conclusions:
- Orlistat is a suitable first-line pharmacotherapy for comprehensive adult and pediatric obesity management.
- Its efficacy in managing co-morbidities supports its role in clinical practice.
- Orlistat's profile positions it as a key option in the pharmacotherapeutic approach to obesity.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...